KR102579524B1 - 폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법 - Google Patents

폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법 Download PDF

Info

Publication number
KR102579524B1
KR102579524B1 KR1020197035080A KR20197035080A KR102579524B1 KR 102579524 B1 KR102579524 B1 KR 102579524B1 KR 1020197035080 A KR1020197035080 A KR 1020197035080A KR 20197035080 A KR20197035080 A KR 20197035080A KR 102579524 B1 KR102579524 B1 KR 102579524B1
Authority
KR
South Korea
Prior art keywords
particles
silica particles
bioactive
bioactive compounds
loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197035080A
Other languages
English (en)
Korean (ko)
Other versions
KR20190142386A (ko
Inventor
춘팡 저우
아담 페일러
파울리나 파슈키에비츠
신 시아
Original Assignee
나노로지카 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나노로지카 에이비 filed Critical 나노로지카 에이비
Publication of KR20190142386A publication Critical patent/KR20190142386A/ko
Application granted granted Critical
Publication of KR102579524B1 publication Critical patent/KR102579524B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/124—Preparation of adsorbing porous silica not in gel form and not finely divided, i.e. silicon skeletons, by acidic treatment of siliceous materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/14—Pore volume
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/16—Pore diameter

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197035080A 2017-05-04 2018-05-03 폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법 Active KR102579524B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1750544-7 2017-05-04
SE1750544 2017-05-04
PCT/EP2018/061436 WO2018202818A1 (en) 2017-05-04 2018-05-03 A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery

Publications (2)

Publication Number Publication Date
KR20190142386A KR20190142386A (ko) 2019-12-26
KR102579524B1 true KR102579524B1 (ko) 2023-09-18

Family

ID=62143135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035080A Active KR102579524B1 (ko) 2017-05-04 2018-05-03 폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법

Country Status (11)

Country Link
US (1) US11285107B2 (cg-RX-API-DMAC7.html)
EP (1) EP3618811B1 (cg-RX-API-DMAC7.html)
JP (1) JP7048642B2 (cg-RX-API-DMAC7.html)
KR (1) KR102579524B1 (cg-RX-API-DMAC7.html)
CN (1) CN110603034A (cg-RX-API-DMAC7.html)
AU (1) AU2018262708B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059099C (cg-RX-API-DMAC7.html)
DK (1) DK3618811T3 (cg-RX-API-DMAC7.html)
ES (1) ES2837675T3 (cg-RX-API-DMAC7.html)
PL (1) PL3618811T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018202818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3618811T3 (da) 2017-05-04 2020-12-21 Nanologica Ab Fremgangsmåde til fremstilling af porøse siliciumdioxidpartikler ladet med mindst én biologisk aktiv forbindelse, der er tilpasset til pulmonal, nasal, sublingual og/eller pharyngeal tilførsel
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
IL286273B2 (en) * 2019-03-24 2025-11-01 Buzzelet Development And Technologies Ltd Cannabis inhalation products and methods of production thereof
JP7394493B2 (ja) * 2019-07-31 2023-12-13 レモネックス インコーポレイテッド 抗癌剤および多孔性シリカ粒子の製造方法
GB201916121D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916117D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916130D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916122D0 (en) 2019-11-06 2019-12-18 Nanologica Ab New compositions
WO2021211738A1 (en) * 2020-04-15 2021-10-21 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for antiviral treatment
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB2355711B (en) 1999-10-27 2003-12-24 Agilent Technologies Inc Porous silica microsphere scavengers
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0118689D0 (en) 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20040242729A1 (en) 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
FI20060428L (fi) 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
US20100116743A1 (en) 2007-06-04 2010-05-13 James Neil Pryor Silica particles and methods of making and using the same
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
CA2698683A1 (en) 2007-09-07 2009-03-12 Epigenesis Pharmaceuticals, Llc Dheas inhalation compositions
WO2009101110A2 (en) 2008-02-11 2009-08-20 Alfonso Garcia-Bennet Method for manufacturing mesoporous materials, materials so produced and use of mesoporous materials.
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP6073788B2 (ja) 2010-09-14 2017-02-01 ナノロジカ アクティエボラーグ 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
WO2016013751A1 (ko) * 2014-07-22 2016-01-28 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
WO2017023407A2 (en) * 2015-06-01 2017-02-09 Stc. Unm Nanobiocomposite compositions and methods
ES2965015T3 (es) * 2016-02-29 2024-04-10 Emplicure Ab Dispositivos de evaporación e inhalación de principios activos
DK3618811T3 (da) 2017-05-04 2020-12-21 Nanologica Ab Fremgangsmåde til fremstilling af porøse siliciumdioxidpartikler ladet med mindst én biologisk aktiv forbindelse, der er tilpasset til pulmonal, nasal, sublingual og/eller pharyngeal tilførsel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Xueting Li, et al., Aerosol droplet delivery of mesoporous silica nanoparticles: A strategy for respiratory-based theraeputics, Nanomedicine, 2015, 11, 1377-1385. (2015.03.25.)*
공개특허공보 제10-2016-0011565호 (2016.02.01.)*

Also Published As

Publication number Publication date
CA3059099A1 (en) 2018-11-08
US11285107B2 (en) 2022-03-29
DK3618811T3 (da) 2020-12-21
JP7048642B2 (ja) 2022-04-05
EP3618811A1 (en) 2020-03-11
CA3059099C (en) 2023-06-27
AU2018262708A1 (en) 2019-11-28
WO2018202818A1 (en) 2018-11-08
ES2837675T3 (es) 2021-07-01
US20200069588A1 (en) 2020-03-05
CN110603034A (zh) 2019-12-20
EP3618811B1 (en) 2020-09-30
KR20190142386A (ko) 2019-12-26
AU2018262708B2 (en) 2021-06-03
PL3618811T3 (pl) 2021-04-06
JP2020518620A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
CA3059099C (en) A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery
AU2009272444B2 (en) Process for improving crystallinity of fluticasone particles
JP4792457B2 (ja) 高度に呼吸に適したインスリンのマイクロ粒子
ES2675575T3 (es) Proceso para preparar partículas vehículo para polvos secos para inhalación
CN110996912A (zh) 用于鼻内递送的干粉组合物
JP2005507881A (ja) 乾燥粉末医薬製剤
AU2007208998A1 (en) A method of producing porous microparticles
JP2020518620A5 (cg-RX-API-DMAC7.html)
CN114206322B (zh) 载体基制剂及相关方法
Carvalho et al. Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges
CN112469395A (zh) 间质性肺病的新治疗
Paul et al. Potentials and challenges of Levodopa particle formulation for treatment of Parkinson’s disease through intranasal and pulmonary delivery
JP2004517834A (ja) 粒子吸入キャリア
JP2021510723A (ja) 吸入型治療薬の高用量送達
Hamedani et al. A novel particle engineering method for the production of inhalable cromolyn sodium powders by a combination of spray drier and nebulizer
Peštálová et al. Modern trends in the formulation of microparticles for lung delivery using porogens: methods, principles and examples
WO2021090013A1 (en) New composition comprising amorphous nanoporous silica particles
HK40014165A (en) A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery
El-Gendy et al. Particle engineering technologies for pulmonary drug delivery
CN116763797B (zh) 一种药物组合微球、其制备方法及其原料组合物
Ong The aerosol performance and physico-chemical properties of co-milled dry powder formulations for high dose delivery
WO2008134817A1 (en) Composite carriers for dry powder inhalation therapy
Meenach et al. Characterization and Aerosol Dispersion Performance of Spray-Dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer
IT202000021292A1 (it) Composizione in forma di polvere a base di microparticelle incorporanti nanoparticelle per la veicolazione di composti terapeutici/diagnostici
Zhang Synthesis of rough-surface carriers for dry powder inhalation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230403

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230727

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230913

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230913

End annual number: 3

Start annual number: 1

PG1601 Publication of registration